Novo Nordisk’s guiding principle is that any excess capital, after
the funding of organic growth opportunities and potential
acquisitions, should be returned to investors. The company applies a
pharmaceutical industry payout ratio to dividend payments, which are
complemented by share repurchase programmes.
In August 2019 the Board of Directors approved to pay an interim
dividend of 3.00 DKK per 0.2 DKK share
At the Annual General Meeting March 2020, the Board of Directors
approved a final dividend of DKK 5.35 for 2019 per share. The total
dividend for 2019 was DKK 8.35 per share, of which DKK 3.00 per share
was paid as interim dividend in August 2019.
Novo Nordisk does not pay a dividend on its holding of treasury shares.